Skip to main content
SpringerLink
Log in

Acute Calcium Disorders

  • Chapter
Book cover Acute Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 1294 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Walser M. Ion association. VI. Interactions between calcium, magnesium, inorganic phosphate, citrate and protein in normal human plasma. J Clin Invest 1961; 40:723–30.

    Article  CAS  PubMed  Google Scholar 

  2. Slomp J, van der Voort PH, Gerritsen RT et al. Albumin-adjusted calcium is not suitable for diagnosis of hyper- and hypocalcemia in the critically ill. Crit Care Med 2003; 31:1389–93.

    Article  CAS  PubMed  Google Scholar 

  3. Moyses-Neto M, Guimaraes FM, Ayoub FH et al. Acute renal failure and hypercalcemia. Ren Fail 2006; 28:153–9.

    Article  CAS  PubMed  Google Scholar 

  4. Newman EM, Bouvet M, Borgehi S et al. Causes of hypercalcemia in a population of military veterans in the United States. Endocr Pract 2006; 12:535–41.

    PubMed  Google Scholar 

  5. Bruzzaniti A, Baron R Molecular regulation of osteoclast activity. Rev Endocr Metab Disord 2006; 7:123–39.

    Article  CAS  PubMed  Google Scholar 

  6. Van Cromphaut SJ, Dewerchin M, Hoenderop JG et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci U S A 2001; 98:13324–9.

    Article  PubMed  Google Scholar 

  7. Bianco SD, Peng JB, Takanaga H et al. Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J Bone Miner Res 2007; 22:274–85.

    Article  CAS  PubMed  Google Scholar 

  8. Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med 2000; 6:442–7.

    Article  CAS  PubMed  Google Scholar 

  9. Suda T, Takahashi N, Udagawa N et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20:345–57.

    Article  CAS  PubMed  Google Scholar 

  10. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; CD003474.

    Google Scholar 

  11. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18–54.

    Article  CAS  PubMed  Google Scholar 

  12. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12:6243s-9s.

    Article  PubMed  Google Scholar 

  13. Stewart AF, Horst R, Deftos LJ et al. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 1980; 303:1377–83.

    Article  CAS  PubMed  Google Scholar 

  14. Gensure RC, Gardella TJ, Juppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005; 328:666–78.

    Article  CAS  PubMed  Google Scholar 

  15. Heath DA. Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management. Endocrinol Metab Clin North Am 1989; 18:631–46.

    CAS  PubMed  Google Scholar 

  16. Silverberg SJ, Bilezikian JP. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab 2006; 2:494–503.

    Article  PubMed  Google Scholar 

  17. Zikusoka MN, Kidd M, Eick G et al. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005; 104:2292–309.

    Article  CAS  PubMed  Google Scholar 

  18. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003; 18 Suppl 3:iii2–iii8.

    CAS  PubMed  Google Scholar 

  19. Davies M. Hyperparathyroidism in X-linked hypophosphataemic osteomalacia. Clin Endocrinol (Oxf) 1995; 42:205–6.

    Article  CAS  Google Scholar 

  20. Van den Berghe G, Van Roosbroeck D, Vanhove P et al. Bone turnover in prolonged critical illness: effect of vitamin D. J Clin Endocrinol Metab 2003; 88:4623–32.

    Article  PubMed  Google Scholar 

  21. Stewart AF, Adler M, Byers CM et al. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982; 306:1136–40.

    Article  CAS  PubMed  Google Scholar 

  22. Lambers TT, Bindels RJ, Hoenderop JG. Coordinated control of renal Ca2+ handling. Kidney Int 2006; 69:650–4.

    Article  CAS  PubMed  Google Scholar 

  23. Suki WN. Effects of diuretics on calcium metabolism. Adv Exp Med Biol 1982; 151:493–500.

    CAS  PubMed  Google Scholar 

  24. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006; 17:1820–32.

    Article  CAS  PubMed  Google Scholar 

  25. Brown EM, Pollak M, Seidman CE et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995; 333:234–40.

    Article  CAS  PubMed  Google Scholar 

  26. Pollak MR, Chou YH, Marx SJ et al. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 1994; 93:1108–12.

    Article  CAS  PubMed  Google Scholar 

  27. Haden ST, Stoll AL, McCormick S et al. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab 1997; 82:2844–8.

    Article  CAS  PubMed  Google Scholar 

  28. Bringhurst FR, Demay MB, Kronenberg HM et al. Hormones and Disorders of Mineral Metabolism. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Textbook of Endocrinology, 10th ed., vol. 1. Philadelphia: Saunders, 2003:1303–74.

    Google Scholar 

  29. Locatelli F, Cannata-Andia JB, Drueke TB et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17:723–31.

    Article  CAS  PubMed  Google Scholar 

  30. Lim P, Dong S, Khoo OT. Intracellular magnesium depletion in chronic renal failure. N Engl J Med 1969; 280:981–4.

    Article  CAS  PubMed  Google Scholar 

  31. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17:897–907.

    Article  CAS  PubMed  Google Scholar 

  32. Dettelbach MA, Deftos LJ, Stewart AF. Intraperitoneal free fatty acids induce severe hypocalcemia in rats: a model for the hypocalcemia of pancreatitis. J Bone Miner Res 1990; 5:1249–55.

    Article  CAS  PubMed  Google Scholar 

  33. Bilezikian JP. Clinical review 51: Management of hypercalcemia. J Clin Endocrinol Metab 1993; 77:1445–9.

    Article  CAS  PubMed  Google Scholar 

  34. Dickerson RN. Treatment of hypocalcemia in critical illness – part 1. Nutrition 2007; 23:358–61.

    Article  PubMed  Google Scholar 

  35. Drop LJ, Laver MB. Low plasma ionized calcium and response to calcium therapy in critically ill man. Anesthesiology 1975; 43:300–6.

    Article  CAS  PubMed  Google Scholar 

  36. Dickerson RN. Treatment of hypocalcemia in critical illness – part 2. Nutrition 2007; 23:436–7.

    Article  PubMed  Google Scholar 

  37. Forster J, Querusio L, Burchard KW et al. Hypercalcemia in critically ill surgical patients. Ann Surg 1985; 202:512–8.

    Article  CAS  PubMed  Google Scholar 

  38. Stoffels K, Overbergh L, Giulietti A et al. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res 2006; 21:37–47.

    Article  CAS  PubMed  Google Scholar 

  39. Lin WJ, Yeh WC. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 2005; 24:206–9.

    Article  CAS  PubMed  Google Scholar 

  40. Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25:332–47.

    Article  CAS  PubMed  Google Scholar 

  41. Shrestha SM, Berry JL, Davies M et al. Biphasic hypercalcemia in severe rhabdomyolysis: serial analysis of PTH and vitamin D metabolites. A case report and literature review. Am J Kidney Dis 2004; 43:e31–5.

    Article  PubMed  Google Scholar 

  42. Akmal M, Bishop JE, Telfer N et al. Hypocalcemia and hypercalcemia in patients with rhabdomyolysis with and without acute renal failure. J Clin Endocrinol Metab 1986; 63:137–42.

    Article  CAS  PubMed  Google Scholar 

  43. Vella A, Gerber TC, Hayes DL et al. Digoxin, hypercalcaemia, and cardiac conduction. Postgrad Med J 1999; 75:554–6.

    CAS  PubMed  Google Scholar 

  44. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981; 50:473–81.

    CAS  PubMed  Google Scholar 

  45. Nussbaum SR, Younger J, Vandepol CJ et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95:297–304.

    Article  CAS  PubMed  Google Scholar 

  46. Body JJ, Lortholary A, Romieu G et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999; 14:1557–61.

    Article  CAS  PubMed  Google Scholar 

  47. Marcus R. Diagnosis and treatment of hyperparathyroidism. Rev Endocr Metab Disord 2000; 1:247–52.

    Article  CAS  PubMed  Google Scholar 

  48. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 2006; 356–60, 515.

    Google Scholar 

  49. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558–67.

    CAS  PubMed  Google Scholar 

  50. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735–44.

    Article  CAS  PubMed  Google Scholar 

  51. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99–102.

    Article  CAS  PubMed  Google Scholar 

  52. Weitzman R, Sauter N, Eriksen EF et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-–May 2006. Crit Rev Oncol Hematol 2007; 62:148–52.

    Article  PubMed  Google Scholar 

  53. Hosking DJ, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 1984; 53:359–68.

    CAS  PubMed  Google Scholar 

  54. Fatemi S, Singer FR, Rude RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992; 50:107–9.

    Article  CAS  PubMed  Google Scholar 

  55. Percival RC, Yates AJ, Gray RE et al. Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J (Clin Res Ed) 1984; 289:287.

    Article  CAS  Google Scholar 

  56. Sandler LM, Winearls CG, Fraher LJ et al. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. Q J Med 1984; 53:165–80.

    CAS  PubMed  Google Scholar 

  57. Van Cromphaut SJ, Stockmans I, Torrekens S et al. Duodenal calcium absorption in dexamethasone-treated mice: functional and molecular aspects. Arch Biochem Biophys 2007; 460:300–5.

    Article  PubMed  Google Scholar 

  58. Huybers S, Naber TH, Bindels RJ et al. Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am J Physiol Gastrointest Liver Physiol 2007; 292:G92–7.

    Article  CAS  PubMed  Google Scholar 

  59. Selby PL, Davies M, Marks JS et al. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol (Oxf) 1995; 43:531–6.

    Article  CAS  Google Scholar 

  60. Perlia CP, Gubisch NJ, Wolter J et al. Mithramycin treatment of hypercalcemia. Cancer 1970; 25:389–94.

    Article  CAS  PubMed  Google Scholar 

  61. Leyland-Jones B. Treatment of cancer-related hypercalcemia: the role of gallium nitrate. Semin Oncol 2003; 30:13–9.

    Article  CAS  PubMed  Google Scholar 

  62. Arumugam GP, Sundravel S, Shanthi P et al. Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage. J Bone Miner Metab 2006; 24:243–7.

    Article  CAS  PubMed  Google Scholar 

  63. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006; 25:541–9.

    Article  CAS  PubMed  Google Scholar 

  64. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007; 9 Suppl 1:S7

    Article  PubMed  Google Scholar 

  65. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341:1611–13.

    Article  CAS  PubMed  Google Scholar 

  66. Cardella CJ, Birkin BL, Rapoport A. Role of dialysis in the treatment of severe hypercalcemia: report of two cases successfully treated with hemodialysis and review of the literature. Clin Nephrol 1979; 12:285–90.

    CAS  PubMed  Google Scholar 

  67. Koo WS, Jeon DS, Ahn SJ et al. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996; 72:424–8.

    Article  CAS  PubMed  Google Scholar 

  68. Goltzman D, Karaplis AC, Kremer R et al. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000; 88:2903–8.

    Article  CAS  PubMed  Google Scholar 

  69. Kebebew E, Duh QY, Clark OH. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. Arch Surg 2004; 139:974–7.

    Article  PubMed  Google Scholar 

  70. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350:1516–25.

    Article  CAS  PubMed  Google Scholar 

  71. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1:323–6.

    Article  CAS  PubMed  Google Scholar 

  72. Shoback DM, Bilezikian JP, Turner SA et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88:5644–9.

    Article  CAS  PubMed  Google Scholar 

  73. Festen-Spanjer B, Haring CM, Koster JB et al. Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia. Clin Endocrinol (Oxf) 2007; doi: 10.1111/j.1365–2265.2007.03027.x.

    Google Scholar 

  74. Silverberg SJ, Rubin MR, Faiman C et al. Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma. J Clin Endocrinol Metab 2007; doi:10.1210/jc.2007–0585.

    Google Scholar 

  75. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993; 22:363–75.

    CAS  PubMed  Google Scholar 

  76. Lin CY, Hsieh KC, Yeh MC et al. Skin necrosis after intravenous calcium chloride administration as a complication of parathyroidectomy for secondary hyperparathyroidism: report of four cases. Surg Today 2007; 37:778–81.

    Article  PubMed  Google Scholar 

  77. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006; 3:438–47.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Intensive Care Medicine, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium

    Sophie J. Van Cromphaut MD, PhD

  2. Laboratory of Experimental Medicine and Endocrinology (Legendo), Catholic University of Leuven, Leuven, Belgium

    Roger Bouillon MD, PhD

Authors
  1. Sophie J. Van Cromphaut MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger Bouillon MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Van Cromphaut, S.J., Bouillon, R. (2008). Acute Calcium Disorders. In: Acute Endocrinology. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-177-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-177-6_4

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-176-9

  • Online ISBN: 978-1-60327-177-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation